SkyePharma has entered into a consultation process that could lead to a reduction of approximately 20 per cent of its 101-strong workforce in Muttenz, Switzerland. The proposed steps are intended to improve the company's competitiveness and generate SFr 2.6 million (£1.8 million) of annual operating costs.
At the same time, SkyePharma has agreed to sub-let part of its laboratory space in Muttenz and sell some of its surplus laboratory equipment to Aenova. The latter plans to use the space to expand its own non-competing oral product development activities. The changes will not affect relationships with existing or potential customers and SkyePharma will continue to provide its existing range of oral and inhalation drug-delivery products.
Looking forward, SkyePharma intends to make greater use of third-party sub-contracting for certain aspects of the oral product development process and Aenova has agreed to be a sub-contractor for this purpose. There will be no transfer or disposal of any business, technology or intellectual property to Aenova.